

Special Issue

Tumor Biomarkers in Precision Oncology: From Non-Coding RNAs to Functional Protein Signatures

Message from the Guest Editors

Tumor biomarkers are central to contemporary oncology, providing essential tools for cancer detection, prognosis, treatment selection, and monitoring of therapeutic response. While a growing number of biomarker candidates have been proposed, many remain insufficiently validated, and clinically robust markers that reliably guide precision oncology are still limited. The rapid evolution of high-throughput sequencing, proteomics, and liquid biopsy technologies has expanded the biomarker landscape beyond traditional protein markers to include a broad spectrum of non-coding RNAs and functional molecular signatures. Overall, despite substantial progress in biomarker discovery, major unmet needs remain in standardization, analytical and clinical validation, and implementation in real-world settings, particularly for early detection and therapy-guided decision-making. For this Special Issue of *Cancers*, we welcome original research and review articles that highlight recent advances and future challenges in tumor biomarker development, including discovery pipelines, functional validation, liquid biopsy approaches, multi-omics integration, and biomarker-guided precision oncology.

Guest Editors

Dr. Caiming Xu

Dr. Silei Sui

Dr. Kainan Wang

Dr. Tikam Chand Dakal

Deadline for manuscript submissions

1 December 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/270835

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)